These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 30840323)

  • 1. Treatment Modalities and Survival in Older Adults with Metastatic Colorectal Cancer in Real Life.
    Gouverneur A; Bezin J; Jové J; Bosco-Lévy P; Fourrier-Réglat A; Noize P
    J Am Geriatr Soc; 2019 May; 67(5):913-919. PubMed ID: 30840323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How are elderly patients treated after a diagnosis of metastatic colorectal cancer in real-life practice? A study in a French teaching hospital.
    Gouverneur A; Rouyer M; Grelaud A; Robinson P; Colombani F; Terrebonne E; Smith D; Fourrier-Réglat A; Noize P
    Fundam Clin Pharmacol; 2017 Feb; 31(1):104-109. PubMed ID: 27600062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study.
    Gouverneur A; Coutureau J; Jové J; Rouyer M; Grelaud A; Duc S; Gérard S; Smith D; Ravaud A; Droz C; Bernard MA; Lassalle R; Forrier-Réglat A; Noize P;
    Clin Colorectal Cancer; 2019 Mar; 18(1):e150-e162. PubMed ID: 30630730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer.
    Vijayvergia N; Li T; Wong YN; Hall MJ; Cohen SJ; Dotan E
    Cancer; 2016 Oct; 122(20):3191-3198. PubMed ID: 27379436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic colorectal cancer prior to expanded RAS assessment: evidence from long-term outcome analysis of a real-life cohort within a dedicated colorectal cancer unit.
    Bertero L; Spadi R; Osella-Abate S; Mariani S; Castellano I; Gambella A; Racca P; Morino M; Cassoni P
    World J Surg Oncol; 2020 Apr; 18(1):65. PubMed ID: 32241284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
    Song A; Eo W; Lee S
    World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-related systemic treatment and survival of patients with metachronous metastases from colorectal cancer.
    Razenberg LG; Creemers GJ; Beerepoot LV; Vos AH; van de Wouw AJ; Maas HA; Lemmens VE
    Acta Oncol; 2016 Dec; 55(12):1443-1449. PubMed ID: 27585122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-dependent differences in first-line chemotherapy in patients with metastatic colorectal cancer: the DISCO study.
    Lund CM; Vistisen KK; Dehlendorff C; Rønholt F; Johansen JS; Nielsen DL
    Acta Oncol; 2018 Nov; 57(11):1445-1454. PubMed ID: 30375911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial.
    Froelich MF; Heinemann V; Sommer WH; Holch JW; Schoeppe F; Hesse N; Baumann AB; Kunz WG; Reiser MF; Ricke J; D'Anastasi M; Stintzing S; Modest DP; Kazmierczak PM; Hofmann FO
    Eur Radiol; 2018 Dec; 28(12):5284-5292. PubMed ID: 29882070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in survival of metastatic colorectal cancer: are the benefits of clinical trials reproduced in population-based studies?
    Mitry E; Rollot F; Jooste V; Guiu B; Lepage C; Ghiringhelli F; Faivre J; Bouvier AM
    Eur J Cancer; 2013 Sep; 49(13):2919-25. PubMed ID: 23642328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4.
    Crosara Teixeira M; Marques DF; Ferrari AC; Alves MF; Alex AK; Sabbaga J; Hoff PM; Riechelmann RP
    Clin Colorectal Cancer; 2015 Mar; 14(1):52-7. PubMed ID: 25442812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.
    Adenis A; de la Fouchardiere C; Paule B; Burtin P; Tougeron D; Wallet J; Dourthe LM; Etienne PL; Mineur L; Clisant S; Phelip JM; Kramar A; Andre T
    BMC Cancer; 2016 Jul; 16():412. PubMed ID: 27389564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.
    Latremouille-Viau D; Chang J; Guerin A; Shi S; Wang E; Yu J; Ngai C
    J Med Econ; 2017 Jan; 20(1):54-62. PubMed ID: 27603498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review.
    Gouverneur A; Salvo F; Berdaï D; Moore N; Fourrier-Réglat A; Noize P
    J Geriatr Oncol; 2018 Jan; 9(1):15-23. PubMed ID: 28844343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of irinotecan-based chemotherapy regimens in elderly Medicare patients with metastatic colorectal cancer.
    Obeidat NA; Pradel FG; Zuckerman IH; DeLisle S; Mullins CD
    Am J Geriatr Pharmacother; 2009 Dec; 7(6):343-54. PubMed ID: 20129255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Cetuximab as First-Line Therapy for Patients With Wild-Type KRAS and Unresectable Metastatic Colorectal Cancer in Real-Life Practice: Results of the EREBUS Cohort.
    Rouyer M; François E; Cunha AS; Monnereau A; Noize P; Robinson P; Droz-Perroteau C; Le Monies de Sagazan A; Jové J; Lassalle R; Moore N; Fourrier-Réglat A; Smith D;
    Clin Colorectal Cancer; 2018 Jun; 17(2):129-139. PubMed ID: 29523416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High- versus low-dose leucovorin in the modified FOLFOX6 regimen for first-line treatment of metastatic colorectal cancer.
    Reynolds J; Chamberland-Tremblay A; Herrington JD; Munoz Maldonado Y; Wong L
    J Oncol Pharm Pract; 2017 Apr; 23(3):173-178. PubMed ID: 26786027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies.
    Patel GS; Ullah S; Beeke C; Hakendorf P; Padbury R; Price TJ; Karapetis CS
    Cancer Med; 2015 Oct; 4(10):1461-71. PubMed ID: 26211512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Metastatic colorectal cancer--analysis of treatment modalities and survival now and then].
    Michl M; Holtzem B; Koch J; Moosmann N; Holch J; Hiddemann W; Heinemann V
    Dtsch Med Wochenschr; 2014 Oct; 139(41):2068-72. PubMed ID: 25268205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
    Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
    Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.